Research analysts at Stifel Nicolaus assumed coverage on shares of Crescent Biopharma (NASDAQ:CBIO – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $28.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 65.68% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the stock. TD Cowen raised shares of Crescent Biopharma to a “strong-buy” rating in a report on Friday, June 20th. Lifesci Capital upgraded shares of Crescent Biopharma to a “strong-buy” rating and set a $22.00 price objective on the stock in a report on Wednesday, June 18th.
Check Out Our Latest Report on CBIO
Crescent Biopharma Trading Down 6.1%
About Crescent Biopharma
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Recommended Stories
- Five stocks we like better than Crescent Biopharma
- Retail Stocks Investing, Explained
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Is IBM’s AI Transformation Powering a Sustained Rally?
- What is the Nikkei 225 index?
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.